Show simple item record

dc.contributor.authorHerrero, Carolina
dc.contributor.authorFuente, Alexandre de la
dc.contributor.authorCasas-Arozamena, Carlos
dc.contributor.authorSebastian, Víctor
dc.contributor.authorPrieto, Martín
dc.contributor.authorArruebo, Manuel
dc.contributor.authorAbalo, Alicia
dc.contributor.authorColás, Eva
dc.contributor.authorMoreno Bueno, Gema 
dc.contributor.authorGil-Moreno, Antonio
dc.contributor.authorVilar, Ana
dc.contributor.authorCueva, Juan
dc.contributor.authorAbal, Miguel
dc.contributor.authorMuinelo-Romay, Laura
dc.contributor.otherUAM. Departamento de Bioquímicaes_ES
dc.date.accessioned2020-06-30T06:49:01Z
dc.date.available2020-06-30T06:49:01Z
dc.date.issued2019-12-12
dc.identifier.citationCancers 11.12 (2019): 1-14en_US
dc.identifier.issn2072-6694 (online)es_ES
dc.identifier.urihttp://hdl.handle.net/10486/691476
dc.description.abstractTumor-derived extracellular vesicles (EVs) are secreted in large amounts into biological fluids of cancer patients. The analysis of EVs cargoes has been associated with patient´s outcome and response to therapy. However, current technologies for EVs isolation are tedious and low cost-e cient for routine clinical implementation. To explore the clinical value of circulating EVs analysis we attempted a proof-of-concept in endometrial cancer (EC) with ExoGAG, an easy to use and highly e cient new technology to enrich EVs. Technical performance was first evaluated using EVs secreted by Hec1A cells. Then, the clinical value of this strategy was questioned by analyzing the levels of two well-known tissue biomarkers in EC, L1 cell adhesion molecule (L1CAM) and Annexin A2 (ANXA2), in EVs purified from plasma in a cohort of 41 EC patients and 20 healthy controls. The results demonstrated the specific content of ANXA2 in the purified EVs fraction, with an accurate sensitivity and specificity for EC diagnosis. Importantly, high ANXA2 levels in circulating EVs were associated with high risk of recurrence and non-endometrioid histology suggesting a potential value as a prognostic biomarker in EC. These results also confirmed ExoGAG technology as a robust technique for the clinical implementation of circulating EVs analysesen_US
dc.description.sponsorshipThis research was funded by Instituto de Salud Carlos III, grant PI17/01919, co-financed by the European Regional Development Fund (FEDER), and by Fundación Científica de la Asociación Española Contra el Cáncer (AECC), Grupos Clínicos Coordinados 2018. Carolina Herrero is supported by a predoctoral i-PFIS fellowship from Instituto de Salud Carlos III (IFI17/00047); Laura Muinelo is supported by Asociación Española Contra el Cáncer (AECC).en_US
dc.format.extent14 pag.es_ES
dc.format.mimetypeapplication/pdfen
dc.language.isoengen
dc.publisherMDPI, Basel, Switzerlanden_US
dc.relation.ispartofCancersen_US
dc.rights© 2019 by the authors. Licensee MDPI, Basel, Switzerlanden_US
dc.subject.otherEVsen_US
dc.subject.otherExoGAGen_US
dc.subject.otherEndometrial canceren_US
dc.subject.otherANXA2en_US
dc.titleExtracellular vesicles-based biomarkers represent a promising liquid biopsy in endometrial canceren_US
dc.typearticleen
dc.subject.ecienciaMedicinaes_ES
dc.relation.publisherversionhttps://doi.org/10.3390/cancers11122000es_ES
dc.identifier.doi10.3390/cancers11122000es_ES
dc.identifier.publicationfirstpage1es_ES
dc.identifier.publicationissue12es_ES
dc.identifier.publicationlastpage14es_ES
dc.identifier.publicationvolume11es_ES
dc.relation.projectIDGobierno de España. PI17/01919,es_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionen
dc.rights.ccReconocimientoes_ES
dc.rights.accessRightsopenAccessen
dc.authorUAMMoreno Bueno, Gema (261604)
dc.facultadUAMFacultad de Medicina


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record